Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Can a drug that lowers “bad” cholesterol — and also raises the so-called “good cholesterol,” HDL — help to prevent ...

WinRevair’s Phase 3 HYPERION trial was stopped early for efficacy, with positive top-line results announced in the month ...

There are a number of emerging therapies in development for lowering lipoprotein(a), and later-stage trials are underway.Interest continues to grow in lipoprotein(a), commonly known as Lp(a), both as ...

Today, anthrax remains one of the deadliest and easiest biological weapons to produce. Yet 80 percent of the U.S. supply of ciprofloxacin is still imported. Moreover, most of those imports, whether ...

The investigational combination of ervogastat plus clesacostat showed efficacy and safety for patients with biopsy-confirmed ...

Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to persistent weakness in demand for the blockbuster human papillomavirus vaccine ...

Key Points Merck aims to boost its business by buying Verona Pharma for $10 billion.Through the deal, it will add Ohtuvayre -- a treatment for COPD -- to its portfolio.With the stock valued at ...

Merck on Tuesday said it will slash $3 billion in costs by the end of 2027 to be fully reinvested to support new product launches and its drug pipeline. The multiyear effort comes as Merck ...

Along with its financial results for the second quarter of 2025, Merck revealed a restructuring plan to save $3 billion by the end of 2027.

Merck posted lower Q2 earnings as vaccine sales dropped, but oncology and animal health segments saw strong growth; 2025 guidance slightly raised.